224 related articles for article (PubMed ID: 35963526)
1. The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
Oun A; Sabogal-Guaqueta AM; Galuh S; Alexander A; Kortholt A; Dolga AM
Neurobiol Dis; 2022 Oct; 173():105837. PubMed ID: 35963526
[TBL] [Abstract][Full Text] [Related]
2. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
[TBL] [Abstract][Full Text] [Related]
3. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
Kim J; Daadi MM
Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
[TBL] [Abstract][Full Text] [Related]
4. Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.
Kim H; Park HJ; Choi H; Chang Y; Park H; Shin J; Kim J; Lengner CJ; Lee YK; Kim J
Stem Cell Reports; 2019 Mar; 12(3):518-531. PubMed ID: 30799274
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 and mitochondria: Recent advances and current views.
Singh A; Zhi L; Zhang H
Brain Res; 2019 Jan; 1702():96-104. PubMed ID: 29894679
[TBL] [Abstract][Full Text] [Related]
8. Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease.
Weykopf B; Haupt S; Jungverdorben J; Flitsch LJ; Hebisch M; Liu GH; Suzuki K; Belmonte JCI; Peitz M; Blaess S; Till A; Brüstle O
Eur J Neurosci; 2019 Feb; 49(4):561-589. PubMed ID: 30656775
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.
Ravinther AI; Dewadas HD; Tong SR; Foo CN; Lin YE; Chien CT; Lim YM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233046
[TBL] [Abstract][Full Text] [Related]
10. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
11. Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
Ohtonen S; Giudice L; Jäntti H; Fazaludeen MF; Shakirzyanova A; Gómez-Budia M; Välimäki NN; Niskanen J; Korvenlaita N; Fagerlund I; Koistinaho J; Amiry-Moghaddam M; Savchenko E; Roybon L; Lehtonen Š; Korhonen P; Malm T
Sci Rep; 2023 Dec; 13(1):22118. PubMed ID: 38092815
[TBL] [Abstract][Full Text] [Related]
12. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of LRRK2 in tauopathies.
Herbst S; Lewis PA; Morris HR
Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 at the Crossroad of Aging and Parkinson's Disease.
Hur EM; Lee BD
Genes (Basel); 2021 Mar; 12(4):. PubMed ID: 33805527
[TBL] [Abstract][Full Text] [Related]
15. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Thakur G; Kumar V; Lee KW; Won C
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337
[TBL] [Abstract][Full Text] [Related]
16. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
17. Generation of induced pluripotent stem cells (IBMSi011-A) from a patient with Parkinson's disease carrying LRRK2 p.I1371V mutation.
Lin HI; Cheng YC; Ko HW; Wen CH; Lu HE; Huang CY; Hsieh PCH; Lin CH
Stem Cell Res; 2019 May; 37():101447. PubMed ID: 31029016
[TBL] [Abstract][Full Text] [Related]
18. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.
Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L
Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418
[TBL] [Abstract][Full Text] [Related]
19. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
[TBL] [Abstract][Full Text] [Related]
20. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
